Promega Executive and Leadership Team

William Linton, the Chairman, Chief Executive Officer & President at Promega, directs the overarching corporate strategy for this biotechnology manufacturer. Overseeing the development of enzymes and molecular biology products, the Chairman, Chief Executive Officer & President ensures alignment across genomics and drug discovery portfolios. This leadership role involves guiding long-term research investments to maintain market dominance in cellular analysis. By fostering a culture of scientific inquiry, William Linton drives the organization toward sustainable growth and technological advancement. The Chairman, Chief Executive Officer & President manages high-level interactions with the board to secure operational stability. Through consistent focus on innovation, Linton shapes the trajectory of the company within the global life sciences sector, ensuring that the product pipeline meets the evolving needs of researchers worldwide while upholding the rigorous standards expected of a leader in the biotechnology industry.

Chris Yarbro, the Chief Financial Officer at Promega, manages the fiscal health and capital allocation strategies for the organization. Overseeing financial planning and analysis, the Chief Financial Officer ensures that resources support the manufacturing of enzymes and protein analysis tools. This leadership role involves optimizing budgetary frameworks to facilitate expansion in the genomics and cellular analysis markets. By monitoring global economic trends, Chris Yarbro mitigates financial risks while supporting the strategic objectives of the executive team. The Chief Financial Officer maintains rigorous oversight of corporate expenditures to ensure efficiency across all manufacturing facilities. Through precise financial modeling and reporting, Yarbro provides the necessary data to inform critical business decisions. This role remains essential for maintaining the financial integrity of the company as the organization scales operations to meet the increasing demand for molecular biology solutions across international markets.

Kristen Yetter, the General Manager and President at Promega, executes the operational strategy and day-to-day management of the company's core business units. Overseeing the manufacturing and distribution of enzymes and cellular analysis products, the General Manager and President ensures that production targets meet the demands of the global biotechnology market. This leadership role involves streamlining internal processes to enhance productivity and quality control. By managing cross-departmental workflows, Kristen Yetter maintains operational excellence across the organization. The General Manager and President works closely with the executive team to implement policies that support the company's mission of advancing molecular biology. Through effective resource management, Yetter drives efficiency in the supply chain and manufacturing operations. This role remains vital for ensuring that the company delivers high-quality products to researchers and clinicians, thereby supporting the overall growth and stability of the business in a competitive industry.

Brian Schiro, the Chief Information Officer at Promega, architects the digital infrastructure required to support complex biotechnology manufacturing processes. Overseeing enterprise systems and data security, the Chief Information Officer ensures that information flows seamlessly across genomics and drug discovery departments. This leadership role involves implementing advanced analytics to improve operational efficiency and product development cycles. By modernizing the technological landscape, Brian Schiro enables the company to maintain a competitive edge in the molecular biology sector. The Chief Information Officer collaborates with other executives to integrate digital solutions that enhance research capabilities and supply chain transparency. Through the deployment of scalable cloud platforms, Schiro supports the global reach of the organization. This role remains vital for protecting intellectual property and ensuring that data-driven insights continue to fuel the scientific advancements that define the company's market position.

Kara Machleidt, the Global Chief Revenue Officer, Strategic Business Lead at Promega, directs the commercial strategy and market expansion efforts for the biotechnology portfolio. Overseeing revenue generation across genomics and protein analysis, the Global Chief Revenue Officer, Strategic Business Lead ensures that sales initiatives align with the specific needs of the drug discovery and genetic identity markets. This leadership role involves identifying new growth opportunities and strengthening relationships with key research institutions. By optimizing the sales funnel, Kara Machleidt drives consistent revenue growth while expanding the company's footprint in international territories. The Global Chief Revenue Officer, Strategic Business Lead coordinates with cross-functional teams to deliver value-added solutions to clients. Through strategic market positioning, Machleidt secures long-term partnerships that reinforce the company's status as a leader in molecular biology. This role remains critical for translating scientific innovation into tangible commercial success on a global scale.

Ash Anderson, the Chief Medical Officer at Promega, provides clinical oversight and scientific guidance for the development of diagnostic and molecular biology products. Overseeing medical affairs, the Chief Medical Officer ensures that all product applications meet the highest standards of clinical relevance and regulatory compliance. This leadership role involves bridging the gap between laboratory research and practical medical application in fields such as genetic identity and drug discovery. By evaluating clinical data, Ash Anderson informs the strategic direction of the product pipeline. The Chief Medical Officer collaborates with internal research teams to validate the efficacy of new biotechnology tools. Through rigorous scientific review, Anderson ensures that the company's offerings address critical challenges in the healthcare and research sectors. This role remains essential for maintaining the credibility and scientific integrity of the organization as the company continues to innovate within the complex landscape of molecular diagnostics.